Latest Blog Posts Tagged "2016 Research Progress"
December 23, 2016
Some of our on-staff PhDs reflect on the work in 2016 that brought us closer to our goal of a world without Parkinson's disease.
December 20, 2016
Herantis Pharma was awarded a $6M grant to study the safety and efficacy of a potential therapy for Parkinson's disease (PD): cerebral dopamine neurotrophic factor (CDNF).
December 08, 2016
Voyager Therapeutics announced results from a trial, supported in early stages by MJFF, to help the brain convert levodopa to dopamine and better control motor symptoms.
December 06, 2016
Rachel Dolhun, MD, and Brian Fiske, PhD, give an overview of the promising Parkinson's research updates made in 2016.
December 01, 2016
Two recently published studies, one MJFF-funded, point to mutations in the GBA gene that may predispose some to cognitive problems with Parkinson's disease.
November 29, 2016
Tools developed by the winners from UC San Francisco and Weill Cornell Medicine could accelerate testing of new Parkinson's treatments by helping researchers design trials and choose study volunteers.
November 18, 2016
Meet the three recipients of The Michael J. Fox Foundation's major 2016 research prizes and see how they help place patients' unmet needs at the forefront of research.
November 10, 2016
The trial showed the therapy is safe and tolerable and that the drug gets into the central nervous system well and reduces levels of alpha-synuclein in blood serum. Phase II expected to begin in 2017.
October 31, 2016
A new drug for levodopa-induced dyskinesia is one step closer to potentially reaching market.
October 26, 2016
An MJFF-funded study identified a new factor that may affect age of PD onset in individuals who carry a LRRK2 mutation.